STOCK TITAN

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

FOSTER CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH) and obesity, today announced that management will be presenting at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11 at 2:15 p.m. ET.

A live audio webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH and obesity. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com


Terns Pharmaceuticals Inc

NASDAQ:TERN

TERN Rankings

TERN Latest News

TERN Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link

About TERN

terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.